E2A-PBX1 exhibited a promising prognosis in pediatric acute lymphoblastic leukemia treated with the CCLG-ALL2008 protocol

• DOI: 10.2147/ott.s115257
• Publication Date: 2016-11-23T01:12:34Z
• Authors: Yixin Hu; Hailong He; Jun Lu; Yi Wang; Peifang Xiao; Jianqin Li; Jie Li; Yina Sun; Hui Lv; Junjie Fan; Yanhua Yao; Yihuan Chai; Shaoyan Hu
• Keywords: White blood cell; Minimal Residual Disease; Clinical endpoint

The objective of this study was to observe the prognosis pediatric patients with E2A-PBX1-positive acute lymphoblastic leukemia (ALL) from treatment CCLG-ALL2008 protocol.Three hundred and forty-nine Chinese pre-B-cell ALL were enrolled in December 2008 September 2013. Of these, 20 E2A-PBX1 expression 223 without gene stratified into two cohorts. Clinical biological characteristics 5-year event-free survival (EFS), relapse-free (RFS), overall (OS) analyzed compared between these groups.The fusion transcript detected 349 (5.7%) patients. Compared gene-negative subgroup, younger age but did not show significant differences white blood cell (WBC) count or gender distribution at primary diagnosis. Moreover, there more inferior karyotypes subgroup (P=0.035). With protocol, showed a favorable response lower minimal residual disease (MRD) levels (<10-4) time point 1 (TP1, P=0.039) no superior steroid histological remission. We also observed promising outcome, EFS reaching 95.0%±4.9% versus 66.3%±3.9% group (P=0.039). However, we find RFS (P=0.061) OS (P=0.113).Our data provided clinical observation Patients benefited well risk-based intensified trial, MRD longer duration though they had